Cancer: Pelvic radiotherapy Cancer Malignant neoplasm of other and ill-defined sites
Conditions
Interventions
Randomised test intervention vs no intervention controls, non-blinded (Phase III)
Sponsors
Record Provided by the NHSTCT Register - 2006 Update - Department of Health
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who are about to undergo a course of radical or adjuvant pelvic radiotherapy for gynaecological, urological or lower gastrointestinal malignancy 2. Patients able to give informed consent to participate 3. Patients with healthy liver function
Exclusion criteria
Exclusion criteria: 1. Patients unable or unwilling to give informed consent 2. Patients who have already started radiotherapy 3. Patients who have a condition precluding sage oral nutrition 4. Patients with compromised liver function 5. Urology patients participating in the IMRT clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Bowel toxicity (assessed using IBD-Q) at week 4 2. Small bowel damage (citrulline/faecal calprotectin) at week 2 and week 4 | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed